Special Issue

Advances in Metastatic Nonsmall Cell Lung Cancer-Implications on Diagnosis and Treatment as We Head towards 2024

Message from the Guest Editors

Non-small-cell lung cancer (NSCLC) has the highest cancer-related mortality rate worldwide to this day. Oncogenes, tumor heterogeneity and variabilities in the tumor microenvironment may all contribute to cancer progression and metastases, with >50% being metastatic at diagnosis (mainly brain, bone, liver, and adrenal glands). In the past decade, advances in identifying driver mutations have completely changed the therapeutic landscape of this disease. Targeted therapies such as osimertinib and other small-molecule tyrosine kinase inhibitors, are now widely used in clinical practice. At the same time, new therapeutic targets are also emerging, greatly extending the life expectancy of patients who carry these alterations. Immunotherapy has also significantly improved the prognosis and survival of NSCLC patients, even for traditionally frail patients who are not candidates for chemotherapy. We are increasingly able to apply the concept of "precision" oncology" in our clinics today and focus on delivering therapies to our patients that are individualized to their specific needs.

Guest Editors

Dr. Nagashree Seetharamu

Division of Hematology/Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA

Dr. Morana Vojnic

Northwell Health Cancer Institute, Lenox Hill Hospital, New York, NY 10021, USA

Deadline for manuscript submissions

closed (31 May 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/161341

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

